Abstract:The emergence of multidrug resistance (MDR) in malignant tumors is one of the major threats encountered currently by many chemotherapeutic agents. Among the various mechanisms involved in drug resistance, P-glycoprotein (P-gp, ABCB1), a member of the ABC transporter family that significantly increases the efflux of various anticancer drugs from tumor cells, and the metabolic enzyme CYP1B1 are widely considered to be two critical targets in overcoming MDR. Unfortunately, no MDR modulator has been approved by the FDA to date. In this study, based on pharmacophore hybridization, bioisosteric and fragment-growing strategies, we designed and synthesized 11 novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors. Among them, the preferred compound A10 exhibited the best MDR reversal activity (IC 50 = 0.25 μM, RF = 44.4) in SW620/AD300 cells, being comparable to one of the most potent third P-gp inhibitor WK-X-34. In parallel, this dual ABCB1/CYP1B1 inhibitory effect drives compound A10 to exhibit a prominent drug resistance reversal activity to doxorubicin (IC 50 = 4.7 μM, RF = 13.7) in ABCB1/CYP1B1-overexpressing DOX-SW620/AD300-1B1 resistant cells, which is more potent than that of the CYP1B1 inhibitor ANF. Furthermore, although compound A2 possessed moderate ABCB1/CYP1B1 inhibitory activities, it showed considerable antiproliferative activity towards drug-resistant SW620/AD300 and MKN45-DDP-R cells, which may be related to the increase of PUMA expression to promote the apoptosis of the drug-resistant MKN45-DDP-R cells as confirmed by proteomics and western blot assay. These results indicated that tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates may provide a fundamental scaffold reference for further discovery of MDR reversal agents.

Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel

Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Novel Benzo Five-Membered Heterocycle Derivatives as P-Glycoprotein Inhibitors: Design, Synthesis, Molecular Docking, and Anti-Multidrug Resistance Activity

Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance

Design, Synthesis and Biological Evaluation of Seco-Dsp/dck Derivatives Reversing P-glycoprotein-mediated Paclitaxel Resistance in A2780/T Cells

Screening Novel, Potent Multidrug-Resistant Modulators from Imidazole Derivatives

Discovery of 2,5-disubstituted furan derivatives featuring a benzamide motif for overcoming P-glycoprotein mediated multidrug resistance in MCF-7/ADR cell

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Exploration of 1,2,3-Triazole-pyrimidine Hybrids As Potent Reversal Agents Against ABCB1-mediated Multidrug Resistance

Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Seco-4-methyl-DCK Derivatives As Potent Chemosensitizers

Discovery of novel third generation P-glycoprotein inhibitors bearing an azo moiety with MDR-reversing effect

Novel betulin derivatives as multidrug reversal agents targeting P-glycoprotein

Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance

Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors

Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell